Meg Krench joined Sanofi Ventures in 2021 with a background in biotech investing and business development. Previously, she worked as part of the External Innovation team at Vertex Pharmaceuticals and at RA Capital, a crossover investment fund. Meg currently serves as a director for Normunity and as an observer for several companies including Draig Therapeutics, Eligo Bioscience, Korsana Biosciences, Quralis, and a stealth immunology company. Meg also supported Sanofi Ventures’ investment in Aliada Therapeutics before its acquisition by Abbvie for $1.4 billion. Meg holds a Ph.D. in Neuroscience from Massachusetts Institute of Technology and a B.S. with Honors in Neuroscience from The Pennsylvania State University. She is also co-chair of the Board of Directors for the New England Venture Network.
BioTech
📍 Based in Cambridge
Direct Professional Email Pattern
AI Outreach Agent Pitch Writer
Compose an personalized, high-converting outreach message targeting their exact investment interest...